How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
Abstract Several randomized controlled trials of anti-estrogens, such as tamoxifen and aromatase inhibitors, have demonstrated up to a 50–65% decrease in breast cancerincidence among high-risk women. Approximately 15% of women, age 35–79 years, in the U.S. meet criteria for breast cancer preventive...
Guardado en:
Autores principales: | Katherine D. Crew, Kathy S. Albain, Dawn L. Hershman, Joseph M. Unger, Shelly S. Lo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9e9b0c4255f248ec9c7a12bc8d55c04e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen.
por: Jennifer M Bordeaux, et al.
Publicado: (2012) -
Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
por: Takayuki Watanabe, et al.
Publicado: (2021) -
Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel N, et al.
Publicado: (2017) -
The antiestrogens tamoxifen and fulvestrant abolish estrogenic impacts of 17α-ethinylestradiol on male calling behavior of Xenopus laevis.
por: Frauke Hoffmann, et al.
Publicado: (2012) -
How can we better integrate the prevention, treatment, control and elimination of neglected tropical diseases with other health interventions? A systematic review
por: Kebede Deribe, et al.
Publicado: (2021)